Description

Ornipressin (8-ornithine vasopressin, POR-8) is a synthetic analog of vasopressin, where ornithine replaces the eighth amino acid. It activates vasopressin V?a receptors, inducing potent vasoconstriction, serving hemostatic functions, and supporting renal blood flow. It has demonstrated efficacy in improving renal hemodynamics and managing hypotension during anesthesia, making it invaluable in cardiovascular, surgical, and renal physiology research. Produced under GMP conditions with ?99% purity, it ensures experimental consistency.

Product Specifications

Mechanism of Action & Research Applications

Ornipressin activates vasopressin V?a receptors on vascular smooth muscle, triggering intracellular calcium release and resulting in smooth muscle contraction and vasoconstriction. This action is utilized experimentally to manage bleeding, control surgical hypotension, and enhance renal perfusion. It has shown effectiveness in restoring blood pressure in anesthetic settings, improving renal blood flow, and treating functional renal failure in cirrhosis models.

Side Effects (For Reference Only)

In research contexts, Ornipressin’s potent vasoconstriction may cause ischemia in targeted tissues, splanchnic perfusion changes, or shifts in blood pressure. Experimental protocols should include monitoring of perfusion and systemic parameters.

Disclaimer

This product is strictly intended for laboratory research use only. It is not approved for human or veterinary use. Please follow institutional safety protocols when handling.